1103 Results for "

anticancer agent

" in MedChemExpress (MCE) Product Catalog:

Products (1103)

Sort by :

Categories

By Targets

Products

728

Doxorubicin hydrochloride

728 Publications Verification

Cat. No.: HY-15142

CAS No.: 25316-40-9

Purity: 99.90%

Synonyms: Hydroxydaunorubicin hydrochloride; ADR

Category:

Infection Quinones Microorganisms Anthraquinones Disease Research Fields

Target:

Topoisomerase ADC Payloads AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye

Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

286

Bortezomib

286 Cited Publications

Cat. No.: HY-10227

CAS No.: 179324-69-7

Purity: 99.91%

Synonyms: PS-341; LDP-341; NSC 681239

Target:

Proteasome NF-κB Apoptosis Autophagy TREM receptor Ligands for Target Protein for PROTAC

Research Areas:

Cancer

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .

Compare